Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18544098 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL694280 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL2024759 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL694279 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL375241 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL5579709 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL694281 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL199927 | 1.00 | HSD17B10 (0.47) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL4002727 | 0.92 | HSD17B10 (0.42) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL1312359 | 0.92 | HSD17B10 (0.53) | HSD17B10CHRM2CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12577259-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4705302-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260022131-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-22 | — | — | US | disclosed |
| US-12473302-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-11-18 | — | — | US | disclosed |
| US-12421211-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4606377-A2 | NOVEL AMINO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| EP-4592295-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20020055469-A1 | AMIDINE INHIBITORS OF SERINE PROTEASES | GENENTECH, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2002030929-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002022575-A1 | AMIDINE INHIBITORS OF SERINE PROTEASES | GENENTECH, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001081347-A2 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
| EP-0923545-A1 | 3-MERCAPTOPYRROLIDINES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1999-06-23 | — | — | EP | disclosed |
| US-5891737-A | ORTHOGONALLY PROTECTED TRIFUNCTIONAL SCAFFOLDS FOR SOLID PHASE SYNTHESIS OF PEPTIDOMIMETIC COMBINATORIAL LIBRARY | ZYMOGENETICS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1998007692-A1 | 3-MERCAPTOPYRROLIDINES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | ZENECA LIMITED (GB) | 1998-02-26 | — | — | WO | disclosed |
| US-5646285-A | ORTHOGONALLY PROTECTED COMPOUNDS | ZYMOGENETICS, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996040732-A1 | COMBINATORIAL NON-PEPTIDE LIBRARIES | ZYMOGENETICS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421211-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | HSD17B10 586/4885CHRM2 1403/4885CHRM1 532/4885 |
| US-12473302-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, DRD3 | HSD17B10 3363/4885CHRM2 177/4885CHRM1 150/4885 |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | HSD17B10 1579/4885CHRM2 2762/4885CHRM1 2001/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | HSD17B10 3136/4885CHRM2 108/4885CHRM1 77/4885 |
| US-12577259-B2 | PCSK9 antagonist compounds | PCSK9, LDLR, PCSK6 | HSD17B10 152/4885CHRM2 411/4885CHRM1 331/4885 |
| US-20020055469-A1 | AMIDINE INHIBITORS OF SERINE PROTEASES | SERPINE1, SERPINC1, TFPI | HSD17B10 2377/4885CHRM2 3742/4885CHRM1 2039/4885 |
| US-20260022131-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | CLN6, NR2E3, CBR3 | HSD17B10 2530/4885CHRM2 140/4885CHRM1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.